Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

6.3K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.3K
The Tumor Microenvironment02:17

The Tumor Microenvironment

2.6K
2.6K
T Cell Types and Functions01:24

T Cell Types and Functions

3.2K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Short BRAF+MEK coinhibition, alone and combined with anti-CD20 immunotherapy, in relapsed or refractory hairy cell leukemia: An investigator-sponsored multi-center phase 2 clinical trial.

HemaSphere·2026
Same author

Clinical and Biological Implications of TP53 Abnormalities in Relapsed/Refractory Multiple Myeloma: The DEDALO Study.

Clinical lymphoma, myeloma & leukemia·2026
Same author

Kenny-Caffey syndrome: nanophthalmos complicated by uveal effusion, presentation and treatment.

Retinal cases & brief reports·2026
Same author

Coevolution of NK and Tumor Cell States Along Multiple Myeloma Progression from Precursor Conditions.

International journal of molecular sciences·2026
Same author

Electrorotation as a tool for the dielectric characterization of tumor plasma cells in multiple myeloma.

Scientific reports·2026
Same author

Mixed Type Autoimmune Hemolytic Anemia: Clinical Severity and Treatment Patterns in a Large Observational Study.

American journal of hematology·2026

Related Experiment Video

Updated: Apr 27, 2026

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

2.0K

Immunological dysregulation in multiple myeloma microenvironment.

Alessandra Romano1, Concetta Conticello2, Maide Cavalli2

  • 1Department of Clinical and Molecular Biomedicine, Haematology Section, University of Catania, Catania, Italy ; Fondazione Veronesi, Roma, Italy ; Division of Hematology, AOU "Policlinico-Vittorio Emanuele", Catania, Italy.

Biomed Research International
|July 12, 2014
PubMed
Summary

Multiple Myeloma (MM) is driven by plasma cells (PC) in bone marrow. The tumor microenvironment and immune system, including myeloid-derived suppressor cells, protect cancer cells and offer novel therapeutic targets.

More Related Videos

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.1K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

12.5K

Related Experiment Videos

Last Updated: Apr 27, 2026

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

2.0K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.1K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

12.5K

Area of Science:

  • Hematology
  • Cancer Immunology
  • Oncology

Background:

  • Multiple Myeloma (MM) is a cancer of plasma cells (PC) in the bone marrow (BM).
  • The tumor microenvironment and host immune system significantly influence MM progression, PC survival, and drug resistance.
  • Components of the bone marrow microenvironment, including stromal cells and extracellular matrix, protect PC from therapy.

Purpose of the Study:

  • To review the role of the immunome in sustaining MM progression.
  • To highlight the emerging role of myeloid-derived suppressor cells (MDSCs) in MM.
  • To discuss the potential of MDSCs as novel therapeutic targets in MM.

Main Methods:

  • Literature review focused on the immunome and microenvironment in Multiple Myeloma.
  • Analysis of the role of myeloid-derived suppressor cells in cancer progression.
  • Exploration of potential therapeutic strategies targeting the immune microenvironment.

Main Results:

  • The host immune system and bone marrow microenvironment are critical for MM cell growth, survival, and drug resistance.
  • Myeloid-derived suppressor cells (MDSCs) play an emerging role in supporting MM progression.
  • Targeting the immunome and specific immune suppressive cells presents potential therapeutic avenues.

Conclusions:

  • The complex interplay between the immune system, microenvironment, and MM cells drives disease progression.
  • Myeloid-derived suppressor cells represent a promising target for novel MM therapies.
  • Further research into immunomodulatory strategies could improve MM treatment outcomes.